Skip to main content

Branded

  • Adapt Pharma gets FDA approval for 2-mg Narcan Nasal Spray
    SILVER SPRING, Md. — The Food and Drug Administration has approved a 2-mg formulation of Adapt Pharma’s Narcan Nasal Spray, the company announced Wednesday. 
     
    The 2-mg dose is approved for use in patients who are opioid dependent and expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts. 
     

  • PhRMA launches Go Boldly campaign

    WASHINGTON — The Pharmaceutical Research and Manufacturers of America on Monday launched its new multi-year advertising and public affairs initiative, Go Boldly. The campaign is aimed at highlighting those in the industry driving innovation and pointing to the opportunity that exists in tackling complex health conditions. 

  • FamilyWize introduces Medicine Cabinet
    BETHLEHEM, Pa. — FamilyWize on Monday announced a new feature for patients looking for the best price on their prescription medications. The FamilyWize Medicine Cabinet, which the company says is the next evolution of its Drug Price Lookup Tool. The Medicine Cabinet allows users to create a personal profile and easily find the lowest price for their prescriptions through FamilyWize’s website and mobile app. 
     

  • Bristol-Myers Squibb decides against accelerated approval for Opdivo/Yervoy combo for lung cancer
    PRINCETON, N.J. — Bristol-Myers Squibb has announced that it will not seek an accelerated regulatory approval for a combination of its Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line treatment for lung cancer. 
     
    The company said the announcement was “based on a review of data available at this time,” and noted that they would not provide additional details to “protect the integrity of ongoing registrational studies.”
     

  • FDA approves Trulance from Synergy Pharmaceuticals
    The Food and Drug Administration has approved Synergy Pharmaceuticals’s Trulance (plecanatide), the company and agency announced Thursday. The drug is indicated to treat adults with chronic idiopathic constipation. It’s the first drug designed to replicate the function of the gastrointestinal peptide uroguanylin.
     

  • Kaléo announces Auvi-Q availability
    RICHMOND, Va. — Kaléo on Thursday announced that its Auvi-Q epinephrine auto-injector would be available by prescription starting Feb. 14. Kaléo announced in October that it would be bringing back the auto-injector, which features voice instructions and automatically retracting needle. 
     

  • FDA approves Allergan’s Rhofade cream
    SILVER SPRING, Md. — The Food and Drug Administration has approved Allergan’s Rhofade (oxymetazoline hydrochloride) cream, the company announced Thursday. The cream is indicated to treat persistent facial redness from rosacea in adults. 
     

  • Lilly to acquire CoLucid Pharmaceuticals
    INDIANAPOLIS and CAMBRIDGE, Mass. — Eli Lilly on Wednesday announced its planned acquisition of CoLucid Pharmaceuticals. The $960 million all-cash transaction is aimed at growing Lilly’s migraine pain management portfolio and will add a potential near-term launch to its late-stage pipeline. 
     
X
This ad will auto-close in 10 seconds